By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl … Read more
By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Collaboration Agreement with Abbott for Phase 3 TECH-LVAD Trial On March 4, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced a collaboration agreement with Abbott for the Phase 3 TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. In August 2024, Cadrenal … Read more
By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical stage, specialty pharmaceutical company that focuses on developing treatments for rare and orphan diseases, initially in the dermatology space. The company is advancing clinical studies to evaluate lead asset QRX003 for the treatment of Netherton … Read more
Toronto-based Wave is a relatively new player in small business financial services, and it’s making its name by building a user-friendly and affordable platform that addresses the unique needs of freelancers, contractors and small business owners. Payroll is Wave’s latest feature. It comes to the platform along with accounting, invoicing and payment processing for small … Read more
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, … Read more
